Xenetic shares slide on acquisition setback
This article was originally published in Scrip
Executive Summary
Xenetic Biosciences, the UK-based company formerly known as Lipoxen, saw its share price on London's AIM slide by 8.6% to 6.63 pence when the markets opened on 15 December, after it announced that the closing of the acquisition of German firm SymbioTec would be delayed. The deal had been slated for completion by 15 December; Xenetic now says it will make a further announcement by 31 December.